Otenabant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Otenabant
Otenabant.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C25H25Cl2N7O
Molar mass 510.4 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]

See also[edit]

References[edit]

  1. ^ Kim, M.; et al. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron, 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057 
  2. ^ Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
  3. ^ http://www.pfizer.com